Vitreoretinal Lymphoma in a Patient with Rheumatoid Arthritis with a History of Methotrexate-associated Lymphoproliferative Disorders.
Naho KurisuTomona HiyamaYosuke HaradaNoriyasu FukushimaNarutaka KatsuyaHiroshi UreshinoTatsuo IchinoheYoshiaki KiuchiPublished in: Ocular immunology and inflammation (2022)
Methotrexate (MTX) may induce immunosuppression and facilitate the onset of lymphoproliferative disorders (LPD). Most cases of MTX-LPD occur in patients with rheumatoid arthritis; the incidence is high in Japan. Vitreoretinal lymphoma (VRL) is a rare non-Hodgkin's lymphoma that can masquerade as steroid-resistant chronic uveitis, leading to fatal diagnostic delay. A 68-year-old woman exhibited optic disc swelling and retinal vasculitis causing floaters in the right eye. She was undergoing long-term MTX treatment for rheumatoid arthritis; she previously had been diagnosed with MTX-LPD, which regressed upon discontinuation of MTX. Steroid therapy was ineffective for optic disc swelling and retinal vasculitis; her best-corrected visual acuity decreased to 20/400. Vitreous biopsy revealed VRL, which was successfully treated with high-dose MTX-based systemic chemotherapy and intravitreal injections of MTX. To our knowledge, this is the first case report of VRL in a patient with an autoimmune disease who have a history of MTX-LPD.
Keyphrases
- high dose
- case report
- rheumatoid arthritis
- optical coherence tomography
- diffuse large b cell lymphoma
- diabetic retinopathy
- optic nerve
- healthcare
- low dose
- ultrasound guided
- stem cells
- risk factors
- squamous cell carcinoma
- vascular endothelial growth factor
- radiation therapy
- juvenile idiopathic arthritis
- interstitial lung disease
- single cell
- hodgkin lymphoma
- locally advanced
- smoking cessation